

**Table 1.103A Any Use and Misuse of Prescription Pain Reliever Subtypes in Past Year: Among People Aged 12 or Older; Misuse of Prescription Pain Reliever Subtypes in Past Year: Among Past Year Any Users of Prescription Pain Reliever Subtypes Aged 12 or Older; Numbers in Thousands, 2019 and 2020**

Pain Reliever Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse		Misuse in Past Year among Past Year Any Users of Pain Reliever Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Pain Reliever Subtypes (2020)
			in Past Year among Total Population (2019)	in Past Year among Total Population (2020)		
<b>ANY PRESCRIPTION PAIN RELIEVER</b>	82,559	75,198	9,724	9,254	9,724	9,254
Hydrocodone Products	43,571	37,657	5,068	4,729	5,068	4,729
Zohydro <sup>®</sup> ER	338	401	35	30	*	*
Oxycodone Products	24,372	21,756	3,185	3,153	3,185	3,153
OxyContin <sup>®</sup>	8,799	7,136	1,207	1,317	1,207	1,317
Tramadol Products	17,183	16,718	1,340	1,513	1,340	1,513
Codeine Products	24,106	19,998	2,380	2,447	2,380	2,447
Morphine Products	5,838	5,541	455	492	455	492
Fentanyl Products	2,530	2,403	269	356	269	356
Buprenorphine Products	2,469	2,605	686	690	686	690
Oxymorphone Products	856	925	234	159	234	*
Demerol <sup>®</sup>	918	394	51	31	51	*
Hydromorphone Products	1,614	1,314	179	219	179	219
Methadone	1,064	1,422	240	229	240	*
Any Other Prescription Pain Reliever <sup>1</sup>	22,829	20,878	930	1,117	930	1,117

\* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

<sup>1</sup> Includes use or misuse of pain relievers containing other active ingredients. Reports of misuse of “any other prescription pain reliever” that correspond only to the specific pain reliever categories shown in the table are excluded from estimates for Any Other Prescription Pain Reliever and are included instead in the relevant pain reliever category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

**Table 1.103B Any Use and Misuse of Prescription Pain Reliever Subtypes in Past Year: Among People Aged 12 or Older; Misuse of Prescription Pain Reliever Subtypes in Past Year: Among Past Year Any Users of Prescription Pain Reliever Subtypes Aged 12 or Older; Percentages, 2019 and 2020**

Pain Reliever Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse	Misuse	Misuse	Misuse
			in Past Year among Total Population (2019)	in Past Year among Total Population (2020)	in Past Year among Any Users of Pain Reliever Subtypes (2019)	in Past Year among Any Users of Pain Reliever Subtypes (2020)
<b>ANY PRESCRIPTION PAIN RELIEVER</b>	30.0	27.2	3.5	3.3	11.8	12.3
Hydrocodone Products	15.8	13.6	1.8	1.7	11.6	12.6
Zohydro <sup>®</sup> ER	0.1	0.1	0.0	0.0	*	*
Oxycodone Products	8.9	7.9	1.2	1.1	13.1	14.5
OxyContin <sup>®</sup>	3.2	2.6	0.4	0.5	13.7	18.5
Tramadol Products	6.2	6.0	0.5	0.5	7.8	9.0
Codeine Products	8.8	7.2	0.9	0.9	9.9	12.2
Morphine Products	2.1	2.0	0.2	0.2	7.8	8.9
Fentanyl Products	0.9	0.9	0.1	0.1	10.6	14.8
Buprenorphine Products	0.9	0.9	0.2	0.2	27.8	26.5
Oxymorphone Products	0.3	0.3	0.1	0.1	27.3	*
Demerol <sup>®</sup>	0.3	0.1	0.0	0.0	5.6	*
Hydromorphone Products	0.6	0.5	0.1	0.1	11.1	16.6
Methadone	0.4	0.5	0.1	0.1	22.5	*
Any Other Prescription Pain Reliever <sup>1</sup>	8.3	7.5	0.3	0.4	4.1	5.4

\* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

<sup>1</sup> Includes use or misuse of pain relievers containing other active ingredients. Reports of misuse of “any other prescription pain reliever” that correspond only to the specific pain reliever categories shown in the table are excluded from estimates for Any Other Prescription Pain Reliever and are included instead in the relevant pain reliever category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

**Table 1.104A Any Use and Misuse of Prescription Pain Reliever Subtypes in Past Year: Among People Aged 12 to 17; Misuse of Prescription Pain Reliever Subtypes in Past Year: Among Past Year Any Users of Prescription Pain Reliever Subtypes Aged 12 to 17; Numbers in Thousands, 2019 and 2020**

Pain Reliever Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse	Misuse	Misuse	Misuse
			in Past Year among Total Population (2019)	in Past Year among Total Population (2020)	in Past Year among Any Users of Pain Reliever Subtypes (2019)	in Past Year among Any Users of Pain Reliever Subtypes (2020)
<b>ANY PRESCRIPTION PAIN RELIEVER</b>	3,980	<i>3,079</i>	567	<i>396</i>	567	<i>396</i>
Hydrocodone Products	767	<i>676</i>	160	<i>107</i>	160	<i>107</i>
Zohydro <sup>®</sup> ER	28	<i>18</i>	7	*	*	*
Oxycodone Products	703	<i>552</i>	164	<i>94</i>	164	<i>94</i>
OxyContin <sup>®</sup>	288	<i>274</i>	69	<i>68</i>	69	*
Tramadol Products	335	<i>190</i>	52	<i>35</i>	52	*
Codeine Products	1,386	<i>1,148</i>	215	<i>128</i>	215	<i>128</i>
Morphine Products	318	<i>181</i>	40	<i>20</i>	40	*
Fentanyl Products	68	<i>33</i>	5	*	*	*
Buprenorphine Products	72	<i>50</i>	10	<i>8</i>	*	*
Oxymorphone Products	47	<i>34</i>	5	<i>13</i>	*	*
Demerol <sup>®</sup>	34	<i>7</i>	4	*	*	*
Hydromorphone Products	12	<i>31</i>	6	<i>5</i>	*	*
Methadone	42	<i>12</i>	16	*	*	*
Any Other Prescription Pain Reliever <sup>1</sup>	1,912	<i>1,313</i>	124	<i>149</i>	124	<i>149</i>

\* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

<sup>1</sup> Includes use or misuse of pain relievers containing other active ingredients. Reports of misuse of “any other prescription pain reliever” that correspond only to the specific pain reliever categories shown in the table are excluded from estimates for Any Other Prescription Pain Reliever and are included instead in the relevant pain reliever category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

**Table 1.104B Any Use and Misuse of Prescription Pain Reliever Subtypes in Past Year: Among People Aged 12 to 17; Misuse of Prescription Pain Reliever Subtypes in Past Year: Among Past Year Any Users of Prescription Pain Reliever Subtypes Aged 12 to 17; Percentages, 2019 and 2020**

Pain Reliever Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse		Misuse in Past Year among Past Year Any Users of Pain Reliever Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Pain Reliever Subtypes (2020)
			in Past Year among Total Population (2019)	in Past Year among Total Population (2020)		
<b>ANY PRESCRIPTION PAIN RELIEVER</b>	16.0	<i>12.3</i>	2.3	<i>1.6</i>	14.2	<i>12.9</i>
Hydrocodone Products	3.1	<i>2.7</i>	0.6	<i>0.4</i>	20.9	<i>15.8</i>
Zohydro <sup>®</sup> ER	0.1	<i>0.1</i>	0.0	*	*	*
Oxycodone Products	2.8	<i>2.2</i>	0.7	<i>0.4</i>	23.3	<i>17.1</i>
OxyContin <sup>®</sup>	1.2	<i>1.1</i>	0.3	<i>0.3</i>	23.8	*
Tramadol Products	1.3	<i>0.8</i>	0.2	<i>0.1</i>	15.6	*
Codeine Products	5.6	<i>4.6</i>	0.9	<i>0.5</i>	15.5	<i>11.2</i>
Morphine Products	1.3	<i>0.7</i>	0.2	<i>0.1</i>	12.5	*
Fentanyl Products	0.3	<i>0.1</i>	0.0	*	*	*
Buprenorphine Products	0.3	<i>0.2</i>	0.0	<i>0.0</i>	*	*
Oxymorphone Products	0.2	<i>0.1</i>	0.0	<i>0.1</i>	*	*
Demerol <sup>®</sup>	0.1	<i>0.0</i>	0.0	*	*	*
Hydromorphone Products	0.0	<i>0.1</i>	0.0	<i>0.0</i>	*	*
Methadone	0.2	<i>0.0</i>	0.1	*	*	*
Any Other Prescription Pain Reliever <sup>1</sup>	7.7	<i>5.3</i>	0.5	<i>0.6</i>	6.5	<i>11.4</i>

\* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

<sup>1</sup> Includes use or misuse of pain relievers containing other active ingredients. Reports of misuse of “any other prescription pain reliever” that correspond only to the specific pain reliever categories shown in the table are excluded from estimates for Any Other Prescription Pain Reliever and are included instead in the relevant pain reliever category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

**Table 1.105A Any Use and Misuse of Prescription Pain Reliever Subtypes in Past Year: Among People Aged 18 or Older; Misuse of Prescription Pain Reliever Subtypes in Past Year: Among Past Year Any Users of Prescription Pain Reliever Subtypes Aged 18 or Older; Numbers in Thousands, 2019 and 2020**

Pain Reliever Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse	Misuse	Misuse	Misuse
			in Past Year among Total Population (2019)	in Past Year among Total Population (2020)	in Past Year among Any Users of Pain Reliever Subtypes (2019)	in Past Year among Any Users of Pain Reliever Subtypes (2020)
<b>ANY PRESCRIPTION PAIN RELIEVER</b>	78,579	72,118	9,158	8,858	9,158	8,858
Hydrocodone Products	42,804	36,981	4,908	4,623	4,908	4,623
Zohydro <sup>®</sup> ER	310	382	28	30	*	*
Oxycodone Products	23,669	21,204	3,020	3,059	3,020	3,059
OxyContin <sup>®</sup>	8,510	6,862	1,138	1,250	1,138	1,250
Tramadol Products	16,848	16,528	1,287	1,478	1,287	1,478
Codeine Products	22,720	18,850	2,165	2,319	2,165	2,319
Morphine Products	5,520	5,360	415	472	415	472
Fentanyl Products	2,462	2,370	264	356	264	356
Buprenorphine Products	2,397	2,555	676	682	676	682
Oxymorphone Products	808	891	228	146	228	*
Demerol <sup>®</sup>	884	386	48	31	48	*
Hydromorphone Products	1,602	1,283	173	213	173	*
Methadone	1,022	1,410	223	229	223	*
Any Other Prescription Pain Reliever <sup>1</sup>	20,916	19,565	807	968	807	968

\* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

<sup>1</sup> Includes use or misuse of pain relievers containing other active ingredients. Reports of misuse of “any other prescription pain reliever” that correspond only to the specific pain reliever categories shown in the table are excluded from estimates for Any Other Prescription Pain Reliever and are included instead in the relevant pain reliever category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

**Table 1.105B Any Use and Misuse of Prescription Pain Reliever Subtypes in Past Year: Among People Aged 18 or Older; Misuse of Prescription Pain Reliever Subtypes in Past Year: Among Past Year Any Users of Prescription Pain Reliever Subtypes Aged 18 or Older; Percentages, 2019 and 2020**

Pain Reliever Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse	Misuse	Misuse	Misuse
			in Past Year among Total Population (2019)	in Past Year among Total Population (2020)	in Past Year among Any Users of Pain Reliever Subtypes (2019)	in Past Year among Any Users of Pain Reliever Subtypes (2020)
<b>ANY PRESCRIPTION PAIN RELIEVER</b>	31.4	28.6	3.7	3.5	11.7	12.3
Hydrocodone Products	17.1	14.7	2.0	1.8	11.5	12.5
Zohydro <sup>®</sup> ER	0.1	0.2	0.0	0.0	*	*
Oxycodone Products	9.5	8.4	1.2	1.2	12.8	14.4
OxyContin <sup>®</sup>	3.4	2.7	0.5	0.5	13.4	18.2
Tramadol Products	6.7	6.6	0.5	0.6	7.6	8.9
Codeine Products	9.1	7.5	0.9	0.9	9.5	12.3
Morphine Products	2.2	2.1	0.2	0.2	7.5	8.8
Fentanyl Products	1.0	0.9	0.1	0.1	10.7	15.0
Buprenorphine Products	1.0	1.0	0.3	0.3	28.2	26.7
Oxymorphone Products	0.3	0.4	0.1	0.1	28.3	*
Demerol <sup>®</sup>	0.4	0.2	0.0	0.0	5.4	*
Hydromorphone Products	0.6	0.5	0.1	0.1	10.8	*
Methadone	0.4	0.6	0.1	0.1	21.8	*
Any Other Prescription Pain Reliever <sup>1</sup>	8.4	7.8	0.3	0.4	3.9	4.9

\* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

<sup>1</sup> Includes use or misuse of pain relievers containing other active ingredients. Reports of misuse of “any other prescription pain reliever” that correspond only to the specific pain reliever categories shown in the table are excluded from estimates for Any Other Prescription Pain Reliever and are included instead in the relevant pain reliever category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

**Table 1.106A Any Use and Misuse of Prescription Pain Reliever Subtypes in Past Year: Among People Aged 18 to 25; Misuse of Prescription Pain Reliever Subtypes in Past Year: Among Past Year Any Users of Prescription Pain Reliever Subtypes Aged 18 to 25; Numbers in Thousands, 2019 and 2020**

Pain Reliever Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse		Misuse in Past Year among Past Year Any Users of Pain Reliever Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Pain Reliever Subtypes (2020)
			in Past Year among Total Population (2019)	in Past Year among Total Population (2020)		
<b>ANY PRESCRIPTION PAIN RELIEVER</b>	8,357	6,858	1,754	<i>1,361</i>	1,754	<i>1,361</i>
Hydrocodone Products	3,607	<i>3,069</i>	855	<i>703</i>	855	<i>703</i>
Zohydro <sup>®</sup> ER	45	29	3	*	*	*
Oxycodone Products	2,497	<i>2,059</i>	615	<i>622</i>	615	<i>622</i>
OxyContin <sup>®</sup>	922	<i>683</i>	266	<i>180</i>	266	<i>180</i>
Tramadol Products	1,220	<i>1,180</i>	228	<i>242</i>	228	<i>242</i>
Codeine Products	2,600	<i>2,086</i>	434	<i>291</i>	434	<i>291</i>
Morphine Products	726	<i>426</i>	96	<i>48</i>	96	*
Fentanyl Products	252	<i>285</i>	49	<i>34</i>	49	*
Buprenorphine Products	286	<i>257</i>	124	<i>49</i>	124	*
Oxymorphone Products	141	<i>142</i>	55	<i>33</i>	*	*
Demerol <sup>®</sup>	50	<i>14</i>	11	<i>3</i>	*	*
Hydromorphone Products	96	<i>48</i>	30	<i>3</i>	*	*
Methadone	79	<i>138</i>	29	<i>10</i>	*	*
Any Other Prescription Pain Reliever <sup>1</sup>	2,794	<i>2,081</i>	207	<i>133</i>	207	<i>133</i>

\* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

<sup>1</sup> Includes use or misuse of pain relievers containing other active ingredients. Reports of misuse of “any other prescription pain reliever” that correspond only to the specific pain reliever categories shown in the table are excluded from estimates for Any Other Prescription Pain Reliever and are included instead in the relevant pain reliever category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

**Table 1.106B Any Use and Misuse of Prescription Pain Reliever Subtypes in Past Year: Among People Aged 18 to 25; Misuse of Prescription Pain Reliever Subtypes in Past Year: Among Past Year Any Users of Prescription Pain Reliever Subtypes Aged 18 to 25; Percentages, 2019 and 2020**

Pain Reliever Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse		Misuse in Past Year among Past Year Any Users of Pain Reliever Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Pain Reliever Subtypes (2020)
			in Past Year among Total Population (2019)	in Past Year among Total Population (2020)		
<b>ANY PRESCRIPTION PAIN RELIEVER</b>	24.8	<i>20.5</i>	5.2	<i>4.1</i>	21.0	<i>19.8</i>
Hydrocodone Products	10.7	<i>9.2</i>	2.5	<i>2.1</i>	23.7	<i>22.9</i>
Zohydro <sup>®</sup> ER	0.1	<i>0.1</i>	0.0	*	*	*
Oxycodone Products	7.4	<i>6.1</i>	1.8	<i>1.9</i>	24.6	<i>30.2</i>
OxyContin <sup>®</sup>	2.7	<i>2.0</i>	0.8	<i>0.5</i>	28.8	<i>26.3</i>
Tramadol Products	3.6	<i>3.5</i>	0.7	<i>0.7</i>	18.7	<i>20.5</i>
Codeine Products	7.7	<i>6.2</i>	1.3	<i>0.9</i>	16.7	<i>13.9</i>
Morphine Products	2.2	<i>1.3</i>	0.3	<i>0.1</i>	13.2	*
Fentanyl Products	0.7	<i>0.9</i>	0.1	<i>0.1</i>	19.5	*
Buprenorphine Products	0.8	<i>0.8</i>	0.4	<i>0.1</i>	43.2	*
Oxymorphone Products	0.4	<i>0.4</i>	0.2	<i>0.1</i>	*	*
Demerol <sup>®</sup>	0.1	<i>0.0</i>	0.0	<i>0.0</i>	*	*
Hydromorphone Products	0.3	<i>0.1</i>	0.1	<i>0.0</i>	*	*
Methadone	0.2	<i>0.4</i>	0.1	<i>0.0</i>	*	*
Any Other Prescription Pain Reliever <sup>1</sup>	8.3	<i>6.2</i>	0.6	<i>0.4</i>	7.4	<i>6.4</i>

\* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

<sup>1</sup> Includes use or misuse of pain relievers containing other active ingredients. Reports of misuse of “any other prescription pain reliever” that correspond only to the specific pain reliever categories shown in the table are excluded from estimates for Any Other Prescription Pain Reliever and are included instead in the relevant pain reliever category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

**Table 1.107A Any Use and Misuse of Prescription Pain Reliever Subtypes in Past Year: Among People Aged 26 or Older; Misuse of Prescription Pain Reliever Subtypes in Past Year: Among Past Year Any Users of Prescription Pain Reliever Subtypes Aged 26 or Older; Numbers in Thousands, 2019 and 2020**

Pain Reliever Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse		Misuse in Past Year among Past Year Any Users of Pain Reliever Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Pain Reliever Subtypes (2020)
			in Past Year among Total Population (2019)	in Past Year among Total Population (2020)		
<b>ANY PRESCRIPTION PAIN RELIEVER</b>	70,222	<i>65,261</i>	7,404	<i>7,498</i>	7,404	<i>7,498</i>
Hydrocodone Products	39,197	<i>33,912</i>	4,053	<i>3,920</i>	4,053	<i>3,920</i>
Zohydro <sup>®</sup> ER	265	<i>353</i>	25	<i>30</i>	*	*
Oxycodone Products	21,172	<i>19,146</i>	2,405	<i>2,437</i>	2,405	<i>2,437</i>
OxyContin <sup>®</sup>	7,588	<i>6,179</i>	872	<i>1,070</i>	872	<i>1,070</i>
Tramadol Products	15,627	<i>15,349</i>	1,059	<i>1,236</i>	1,059	<i>1,236</i>
Codeine Products	20,121	<i>16,763</i>	1,731	<i>2,028</i>	1,731	<i>2,028</i>
Morphine Products	4,794	<i>4,934</i>	319	<i>424</i>	319	<i>424</i>
Fentanyl Products	2,210	<i>2,084</i>	215	<i>322</i>	215	<i>322</i>
Buprenorphine Products	2,110	<i>2,298</i>	552	<i>633</i>	552	<i>633</i>
Oxymorphone Products	667	<i>749</i>	173	<i>113</i>	*	*
Demerol <sup>®</sup>	834	<i>372</i>	37	<i>28</i>	37	*
Hydromorphone Products	1,506	<i>1,236</i>	143	<i>210</i>	143	*
Methadone	944	<i>1,272</i>	194	<i>219</i>	194	*
Any Other Prescription Pain Reliever <sup>1</sup>	18,122	<i>17,484</i>	600	<i>835</i>	600	<i>835</i>

\* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

<sup>1</sup> Includes use or misuse of pain relievers containing other active ingredients. Reports of misuse of “any other prescription pain reliever” that correspond only to the specific pain reliever categories shown in the table are excluded from estimates for Any Other Prescription Pain Reliever and are included instead in the relevant pain reliever category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

**Table 1.107B Any Use and Misuse of Prescription Pain Reliever Subtypes in Past Year: Among People Aged 26 or Older; Misuse of Prescription Pain Reliever Subtypes in Past Year: Among Past Year Any Users of Prescription Pain Reliever Subtypes Aged 26 or Older; Percentages, 2019 and 2020**

Pain Reliever Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse	Misuse	Misuse	Misuse
			in Past Year among Total Population (2019)	in Past Year among Total Population (2020)	in Past Year among Any Users of Pain Reliever Subtypes (2019)	in Past Year among Any Users of Pain Reliever Subtypes (2020)
<b>ANY PRESCRIPTION PAIN RELIEVER</b>	32.4	29.9	3.4	3.4	10.5	11.5
Hydrocodone Products	18.1	15.5	1.9	1.8	10.3	11.6
Zohydro <sup>®</sup> ER	0.1	0.2	0.0	0.0	*	*
Oxycodone Products	9.8	8.8	1.1	1.1	11.4	12.7
OxyContin <sup>®</sup>	3.5	2.8	0.4	0.5	11.5	17.3
Tramadol Products	7.2	7.0	0.5	0.6	6.8	8.0
Codeine Products	9.3	7.7	0.8	0.9	8.6	12.1
Morphine Products	2.2	2.3	0.1	0.2	6.7	8.6
Fentanyl Products	1.0	1.0	0.1	0.1	9.7	15.4
Buprenorphine Products	1.0	1.1	0.3	0.3	26.2	27.5
Oxymorphone Products	0.3	0.3	0.1	0.1	*	*
Demerol <sup>®</sup>	0.4	0.2	0.0	0.0	4.4	*
Hydromorphone Products	0.7	0.6	0.1	0.1	9.5	*
Methadone	0.4	0.6	0.1	0.1	20.5	*
Any Other Prescription Pain Reliever <sup>1</sup>	8.4	8.0	0.3	0.4	3.3	4.8

\* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

<sup>1</sup> Includes use or misuse of pain relievers containing other active ingredients. Reports of misuse of “any other prescription pain reliever” that correspond only to the specific pain reliever categories shown in the table are excluded from estimates for Any Other Prescription Pain Reliever and are included instead in the relevant pain reliever category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.